Compositions and methods for treating refractory seizures
AssigneesThe Johns Hopkins University, Kennedy Krieger Institute, Inc.
InventorShilpa D. Kadam
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of seizures. More specifically, the present invention provides compositions and methods for treating refractory seizures in neonates. In one embodiment, the method comprises the steps of (a) administering to the patient an amount of a KCC2 agonist and/or trkB antagonist effective to restore KCC2 expression to normal physiological levels; and (b) administering to the patient an effective amount of an anti-seizure medication.
Claims17
A method for treating refractory seizures in a neonatal patient comprising the steps of:
- a. administering to the patient an amount of a KCC2 agonist and/or trkB antagonist effective to restore KCC2 expression to normal physiological levels;
- and
- b. administering to the patient an effective amount of an anti-seizure medication.
A method for treating refractory seizures in a neonatal patient comprising the steps of:
- a. administering to the patient an amount of ANA-12 and/or CLP290 effective to restore KCC2 expression to normal physiological levels;
- and
- b. administering to the patient an effective amount of an anti-seizure medication.
A method for treating refractory seizures in a neonatal patient comprising the steps of:
- a. administering to the patient an amount of ANA-12 and/or CLP290 effective to restore KCC2 expression to normal physiological levels;
- and
- b. administering to the patient an effective amount of phenobarbital.
A method for treating refractory seizures in a patient comprising the steps of:
- a. administering to the patient an effective amount of an agent that increases KCC2 expression back to normal levels, wherein the seizure downregulates KCC2 expression;
- and
- b. administering to the patient an effective amount of an anti-seizure medication.
A method for treating ischemia-related seizures in a neonatal patient comprising the steps of:
- a. administering a KCC2 agonist and/or a trkB antagonist in an amount(s) effective to restore KCC2 expression back to normal physiological levels;
- and
- b. administering a transient dose of an anti-seizure medication in an amount effective to stop the seizures.
16-19. (canceled)
Dependencies are inferred from the claim text.